Investor · 1 deal
Every published round CEPI took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Vaxxas | Grant | 19 Jan 2023 | ≤$6.4m | Participant | @AuManufacturing (20 Jan 2023), Brandon BioCatalyst portfolio, Brandon Capital portfolio, @AuManufacturing (19 Jan 2023) |
Companies CEPI has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Vaxxas | Biotech/MedTech company | 19 Jan 2023, Grant | 1 | 0 |
Fund closes reported for CEPI, as distinct from the investments it has made.
Companies CEPI has backed that another company then bought. An exit for the holding, not a deal CEPI did.
Stories naming CEPI. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Vaxxas reports encouraging interim Phase I results for its needle-free microarray-patch COVID-19 vaccine, with strong antibody responses and no serious adverse events, ahead of planned regulatory applications in Australia and the US.
Vaxxas has appointed 23-year Pfizer veteran Dr Rochelle Chaiken as chief medical officer; the announcement also recaps the vaccine-patch company's early backing by OneVentures, Brandon Capital and others.
Vaxxas partners with CEPI, which will fund preclinical testing of its needle-free vaccine patch for mRNA vaccines, work that could remove cold-storage needs and widen global access to such vaccines.
Also Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing